These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer. Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417 [TBL] [Abstract][Full Text] [Related]
7. Biodistribution study of Sakmár M; Kozempel J; Kučka J; Janská T; Štíbr M; Vlk M; Šefc L Nucl Med Biol; 2024; 130-131():108890. PubMed ID: 38402673 [TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
9. Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. Takalkar A; Adams S; Subbiah V Exp Hematol Oncol; 2014; 3():23. PubMed ID: 25243101 [TBL] [Abstract][Full Text] [Related]
10. New radiopharmaceutical agents for the treatment of castration-resistant prostate cancer. Maffioli L; Florimonte L; Costa DC; Correia Castanheira J; Grana C; Luster M; Bodei L; Chinol M Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):420-38. PubMed ID: 26222274 [TBL] [Abstract][Full Text] [Related]
11. Development of separation technology for the removal of radium-223 from targeted thorium conjugate formulations. Part I: purification of decayed thorium-227 on cation exchange columns. Frenvik JO; Dyrstad K; Kristensen S; Ryan OB Drug Dev Ind Pharm; 2017 Feb; 43(2):225-233. PubMed ID: 27628177 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and characterization of lanthanum phosphate nanoparticles as carriers for (223)Ra and (225)Ra for targeted alpha therapy. Rojas JV; Woodward JD; Chen N; Rondinone AJ; Castano CH; Mirzadeh S Nucl Med Biol; 2015 Jul; 42(7):614-20. PubMed ID: 25900730 [TBL] [Abstract][Full Text] [Related]
13. Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results. Trencsényi G; Csikos C; Képes Z Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203834 [TBL] [Abstract][Full Text] [Related]
14. Nano-hydroxyapatite radiolabeled with radium dichloride [ Gemini-Piperni S; Ricci-Junior E; İlem-Özdemir D; da Silva Batista B; Alencar LMR; Rossi AM; Santos-Oliveira R Colloids Surf B Biointerfaces; 2023 Mar; 223():113174. PubMed ID: 36746067 [TBL] [Abstract][Full Text] [Related]
15. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Dorff TB; Agarwal N Asian J Androl; 2018; 20(3):215-220. PubMed ID: 29553053 [TBL] [Abstract][Full Text] [Related]
16. Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases. Patel CM; Wadas TJ; Shiozawa Y Molecules; 2021 Apr; 26(8):. PubMed ID: 33918705 [TBL] [Abstract][Full Text] [Related]
17. Bone-targeting radiopharmaceuticals including radium-223. Brady D; Parker CC; O'Sullivan JM Cancer J; 2013; 19(1):71-8. PubMed ID: 23337760 [TBL] [Abstract][Full Text] [Related]
18. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride. Pacilio M; Ventroni G; De Vincentis G; Cassano B; Pellegrini R; Di Castro E; Frantellizzi V; Follacchio GA; Garkavaya T; Lorenzon L; Ialongo P; Pani R; Mango L Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):21-33. PubMed ID: 26266887 [TBL] [Abstract][Full Text] [Related]
19. Integrating bone targeting radiopharmaceuticals into the management of patients with castrate-resistant prostate cancer with symptomatic bone metastases. Blacksburg SR; Witten MR; Haas JA Curr Treat Options Oncol; 2015 Mar; 16(3):325. PubMed ID: 25777571 [TBL] [Abstract][Full Text] [Related]
20. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL). Yoshida S; Takahara T; Arita Y; Ito M; Hayakawa S; Oguchi T; Komai Y; Numao N; Yuasa T; Inoue M; Ushijima H; Kudo S; Shimano Y; Nakamura Y; Uchida Y; Uehara S; Tanaka H; Yaegashi H; Izumi K; Yokoyama M; Matsuoka Y; Yoshioka Y; Konishi K; Nakanishi K; Nagahara A; Hirakawa A; Koike R; Koga F; Nishimura K; Mizokami A; Yonese J; Kageyama Y; Yoshimura R; Fujii Y BMC Urol; 2023 Mar; 23(1):33. PubMed ID: 36879257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]